Search - tctmd.com

Displaying 1 - 20 of 40

Sort: Relevancy | Date

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

News Conference News European Congress on Obesity 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

News Conference News AHA 2024

GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes

Michael O'Riordan

November 17, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

April 06, 2024

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

August 30, 2023

Oral, Daily Semaglutide Cuts Pounds in Nondiabetic Patients: OASIS 1

News Conference News ADA 2023

Oral, Daily Semaglutide Cuts Pounds in Nondiabetic Patients: OASIS 1

June 29, 2023

Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention

News Conference News ADA 2023

Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention

Michael O'Riordan

June 28, 2023

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

News Conference News LINC 2023

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

June 07, 2023

In CABG/PCI Decisions for Left Main Disease, Diabetes ‘Still Matters’

News Conference News CRT 2023

In CABG/PCI Decisions for Left Main Disease, Diabetes ‘Still Matters’

Yael L. Maxwell

March 01, 2023

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

News Conference News AHA 2022

‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE

Michael O'Riordan

November 06, 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

Dapagliflozin Boosts Health Status Across LVEF Range

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

May 23, 2022

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

October 08, 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

News Conference News AHA 2020

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

Michael O'Riordan

November 19, 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.